NEW YORK (GenomeWeb News) – Rubicon Genomics said today that molecular diagnostics company Agendia will use Rubicon's whole-genome RNA amplification technology with Agendia's breast cancer diagnostic tests.
Under a clinical supply agreement, Agendia will incorporate Rubicon's TransPlex technology into the analysis of formalin fixed, paraffin-embedded patient samples for use in testing with its Symphony suite of breast cancer diagnostics.
Ann Arbor, Mich.-based Rubicon said its TransPlex kits are aimed at improving the quality and quantity of nucleic acids extracted from FFPE samples to enable accurate and consistent analysis of molecular diagnostic tests.
In a statement, Rubicon CEO James Koziarz called the deal an important milestone for his firm. "This supply agreement with cancer diagnostics pioneer Agendia represents our first large-scale commercial partnership with a provider of clinical diagnostic tests, and we expect it to be the first of many going forward," he said.
Financial and other terms of the deal were not disclosed.